The University of Oxford Isis Fund I invested in Oxtex, a company specializing in a groundbreaking surgical implant device designed to facilitate skin expansion for reconstructive surgery.
Information on the Target
Oxtex is an innovative company that has developed a cutting-edge surgical implant device to address a critical issue in reconstructive surgery—the lack of sufficient skin in areas requiring reconstruction. This groundbreaking device leverages the unique ability of skin to grow when subjected to controlled tension, offering a solution to enhance surgical outcomes and improve patient recovery.
The company's advancements have not gone unnoticed; Oxtex received the OBN Bioscience award for Best Emerging MedTech in 2011, as well as the accolade for Best New Medtech Product in 2012, highlighting its potential and recognition within the medical technology field.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The reconstructive surgery industry is evolving rapidly, driven by technological advancements and a growing demand for effective and minimally invasive surgical p
Similar Deals
Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV → Oxford Endovascular
2023
Lonsdale Capital Partners → Todays Dental
2023
Chrystal Capital Partners LLP → EMMAC Life Sciences Group
2023
University of Oxford Isis Fund I and Parkwalk Funds → Brainomix
2023
東京大学協創プラットフォーム開発株式会社 → STORM Therapeutics Ltd
2023
University of Oxford Isis Fund I
invested in
Oxtex
in 2023
in a Venture Debt deal